Apollo Acquires 37% Stake in Syntegon as Pharmaceutical Packaging Giant Eyes North American Expansion
核心洞察
Apollo-managed funds are acquiring a 37% minority stake in Syntegon (搜索), the pharmaceutical and biotech packaging equipment manufacturer, while CVC Capital Partners (搜索) retains 63% ownership.
Syntegon (搜索) posted record revenue of €1.75 billion in 2025 with EBITDA rising 27% year-on-year to €282 million, representing a quadrupling of operating profit since CVC's 2019 investment.
The strategic partnership aims to accelerate Syntegon (搜索)'s expansion into North American markets and capitalize on aftermarket services from its 72,000 installed systems worldwide.
CVC Capital Partners (搜索) has announced that Apollo-managed funds are acquiring a 37% minority stake in Syntegon (搜索), the pharmaceutical and biotech packaging and processing equipment manufacturer, in a transaction that positions the Stuttgart-based company for accelerated growth in North American markets.
The deal, announced this morning, leaves CVC holding the remaining 63% of shares, with closing subject to customary regulatory approvals. Financial terms were not disclosed.
Record Financial Performance Drives Strategic Partnership
Syntegon (搜索) posted record revenue of €1.75 billion in 2025, with EBITDA rising 27% year-on-year to €282 million—representing a quadrupling of operating profit since CVC's original investment in 2019. The company operates across the full pharmaceutical, biotechnology and food manufacturing lifecycle and holds approximately 2,000 patents and patent applications.
CVC outlined the strategic rationale for bringing in Apollo as a minority partner, centering on two key areas: US market penetration and aftermarket services expansion.
North American Market Focus and Service Revenue Opportunity
Apollo's North American expertise is expected to support Syntegon (搜索)'s push into what the company describes as "mission-critical and largely non-cyclical" end markets, where regulatory complexity and high switching costs create durable competitive moats.
The second strategic pillar focuses on service revenue opportunities. Syntegon (搜索) manages the world's largest installed base in its sector, with approximately 72,000 highly complex systems across pharma, biotech and food production, representing what the company characterizes as a significant and largely untapped opportunity for lifecycle services, upgrades and compliance support.
Innovation Pipeline and Recent Acquisitions
Innovation remains central to Syntegon (搜索)'s growth strategy. The company recently launched SynTiso (搜索), described as the world's first gloveless high-speed filling line for liquid pharmaceuticals—a development with direct implications for sterile manufacturing operations seeking to reduce contamination risk and improve throughput.
Recent M&A activity has further broadened the portfolio. The 2024 acquisition of Telstar (搜索) strengthened Syntegon (搜索)'s liquid pharma capabilities, while the 2023 majority stake in Klenzaids (搜索) extended its footprint across Asian markets.
Leadership Perspectives on Strategic Partnership
CEO Torsten Türling, who will continue to lead the business, described the transaction as "a milestone," adding that Apollo brings "valuable new momentum" alongside CVC's continued strategic oversight.
Marc Strobel, Chairman of the Supervisory Board of Syntegon (搜索) and Partner at CVC, said: "The team around CEO Torsten Türling has done an outstanding job establishing the company as a leading provider in highly regulated and technologically complex markets. Bringing on board a minority shareholder offers the best conditions to further accelerate Syntegon's growth globally."
Jeremy Honeth, Partner, Hybrid Value at Apollo, added: "Syntegon (搜索) has established itself as a technology leader at the heart of mission-critical pharma, biotech and food supply chains. Together with CVC and management, we see a clear path to continue this strong growth trajectory, particularly in North America and we are excited to support Syntegon in this next phase of its development."